Previous 10 | Next 10 |
home / stock / otsky / otsky news
Summary Vera’s phase 2b ORIGIN data was underwhelming with lower than expected proteinuria reduction ~31% even at 9 months. We believe Atacicept’s commercial opportunity in IgAN is questionable due to the high degree of competition from KDNY, Otsuka, and Remegen. VERA ...
Summary Aurinia has been facing many problems. Potential sales chatter may be a result of its problems. However, I see little reason for big pharma to buy AUPH. Aurinia’s ( AUPH ) price movement over the last 12 months seems predicated on 3 things - key ma...
The success of a pivotal study of Rexulti in Alzheimer's-associated agitation brings an underserved market worth $1 billion or more per year into reach. First quarter results saw better-than-expected sales growth and margins, but the launch of Vyepti continues to underwhelm. In ad...
The most recent two hottest potatoes in the biotech arena are Aurinia Pharmaceuticals and Seagen. While the latter is mostly/recently associated with an upcoming Merck buyout, the former has been associated with many big pharma names. It's clear (to us) that AUPH should be on the ...
Centessa Pharmaceuticals (NASDAQ:CNTA) stock fell ~11% premarket June 2, after the said it will discontinue developing lixivaptan for a type of kidney disease. The company will discontinue development of lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) including both a...
Takeda Pharmaceutical will be able to deliver stellar growth during the next decade. China and emerging markets will be a key driver of growth. The current share price is very undervalued considering the long term growth prospects. For further details see: Takeda Pharmac...
Ginkgo Bioworks (DNA) went public last September through an SPAC deal with Soaring Eagle Acquisition Corporation, a blank-check company led by former MGM CEO Harry Sloan. However, the stock has nosedived in price since its market debut. In addition, given an ongoing investigation into the com...
Biotech company Cassava Sciences (SAVA) is known for its Alzheimer’s drug, currently in phase three clinical trials. The stock has gained triple digits so far this year. However, with the SEC investigating claims that the company allegedly manipulated its prior clinical trial results, ...
The sale of COVID-19 vaccines helped Moderna’s (MRNA) revenue soar over the past few quarters. However, its shares plunged nearly 14% in price on December 10 after disappointing results from its experimental seasonal flu shot. So, let’s discuss if it is wise to buy the dip in th...
Aurinia Pharmaceuticals (NASDAQ:AUPH) will report its Q2 2021 earnings after the closing bell today and investors will want to pay attention to sales and any color management provides on its lupus drug Lupkynis (voclosporin). Lupkynis just won FDA approval in January as the first oral th...
News, Short Squeeze, Breakout and More Instantly...
Otsuka Holdings Co. Ltd. ADR Company Name:
OTSKY Stock Symbol:
OTCMKTS Market:
Tuesday, IGC Pharma Inc (NYSE:IGC) released interim data from its Phase 2 clinical trial of IGC-AD1 for agitation in dementia associ...
Wednesday, IGC Pharma Inc (NYSE:IGC) announced the results of an interim analysis of its ongoing Phase 2 trial of IGC-AD1 for Agitation i...